Thera-SAbDab

LENZILUMAB

>   Structural Summary
TherapeuticLenzilumab
TargetCSF2
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Preregistration
Estimated Status (October '21)Active
Recorded Developmental TechnologyHumaneering Technology
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedHumanigen, KaloBios Pharmaceuticals
Conditions Approvedna
Conditions ActiveCOVID-19, Cytokine release syndrome, B-cell lymphoma, Drug hypersensitivity, Precursor cell lymphoblastic leukaemia-lymphoma, Graft-versus-host disease
Conditions DiscontinuedAsthma, Rheumatoid arthritis, Chronic myelomonocytic leukaemia, Solid tumours
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy